Collectionner le produit
Détails du produit
Synonyms
CD73, NT5E, 5'-Nucleotidase, 5'-NT, NT5, NTE
Source
Cynomolgus CD73, His Tag (CD3-C52H9) is expressed from human 293 cells (HEK293). It contains AA Trp 27 - Cys 554 (Accession # EHH53214.1).
Predicted N-terminus: Trp 27
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 60.0 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Cynomolgus CD73, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Cynomolgus CD73, His Tag (Cat. No. CD3-C52H9) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD73 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).
Protocol
Bioactivity-SPR
Anti-CD73 Antibody captured on Protein A Chip can bind Cynomolgus CD73, His Tag (Cat. No. CD3-C52H9) with an affinity constant of 0.313 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity
Measured by its ability to hydrolyze the 5’-phosphate group from the substrate adenosine-5’-monophosphate (AMP). The specific activity is > 50,000 pmol/min/μg (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
5'-nucleotidase
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
36 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
